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prerequisite for activation of neurohormonal mechanisms. 
When cardiac output decreases after myocardii damage, 
neurohonnones are activated to preserve circulatory ho- 
meostasis. Therefore, the severity of impairment insystolic 
function may relate to the degree of neurohumoral ctiva- 
tion. In contrast, it may be hypothesized that patients with 
heart failure and preserved systolic function may not dem- 
onstrate an activation of the neurohumoral mechanisms. 
The Studies of Left Ventricular Dysfunction (SOLVD) 
Registry was designed to examine the clinical outcome of 
patients with a broader spectrum of left ventricular dysfunc- 
tion (ejection fraction 545% or radiologically confirmed 
diagnosis of congestive heart failure) than that of the main 
SOLVD trials, which enrolled patients with an ejection 
iiaction ~35%. Among patients in the SOLVD Registry who 
presented with congestive heart failure and evidence of 
pulmonary congestion, we compared neurohormonal levels 
between patients with a left ventricular ejection fraction 
~45% and au ejection fraction >45%. 
Methods 
Study de&u. The SOLVD program was a multicenter 
prognun of research iuto left ventricular dy&mction and 
congestive heart faihue. It included two trials and a registry. 
The prevention trial showed that enalapril, an angiotensin- 
converting enzyme inhibitor, prevented the development of 
symptoms of congestive heart ihihue in patients who had a 
left ventricular ejection fraction r35% and were not receiv- 
ing therapy for heart failure (8). The treatment trial demon- 
strated that enah@ reduced the incidence of death in 
patients with mild to moderate congestive heart failure 
(mainly New York Heart Association classes II and III with 
left ventricular ejection fraction 135%) and symptoms of 
heart failure requiring tteatment (9). The SOLVD Registry 
study was conducted in 18 of the 23 SOLVD centers. 
Patients with an &ction fraction 50.45% or a radiilogically 
co&med disc- diagnosis of congestive heart fhilure 
during the recruitment period (January 1, I!#8 to February 
28.1989) were invited to patticipate in the registry. Patients 
with nonvalvular congeuital heart disease, any noncmdiac 
life-threatenin disease, lack of reliable means of follow-up 
or failure to consent to participate wb~ e&ded. Baseline 
information that was abstracted fronn the&ii included the 
followiug: demogmphic data, clinical history, physical ex- 
amination, ejection IMion, etiology of the disease, chest 
X-ray findings, medication used, elmogram (ECG) 
and laboratory results. 
From the 6,273 patients recruited into the SOLVD Reg- 
istry, a subgroup of 898 patients were randomly selected 
afbr strati6cation by etiology (36% of patients with ischemic 
or hypertensive heart disease and 100% of patients with 
other etiolo9ies). Details of the registry methods and sam- 
pIin procedure have been previously published (IO). In this 
subgroup, a detailed history was obtained and physical 
examination, a Wodimensional echocauhogram including 
ejection frsction, chest X-ray film, 12-M ECG and walk 
test were done. Ofthese 8% patients, a subset of41 patients 
was identified retrospectively as having an ejection fraction 
>45% and pulmonary congestion on chest X-ray film, 
whereas another 89 patients were identified as having both 
pulmonary edema on chest X-ray film and an &ction 
fnrction s45%. The present analyses were condu@d on this 
sample. In addition, nemohormonal measurements were 
made on 56 age-matched conml subjects with 110 history or 
physical findings of heart disease or hypertension. None 
were taking medications known to inihtence neurohor- 
mows. Men composed 76% of the control group and the 
averageagewas56* 12years(range37to80). 
The study protocol was approved by the local hospital . 
review boards and the National Institutes of Health. AU 
control subjects and patients provided written informed 
wnsent to participate in the study. 
m mwmWme& An intravenous cant& 
was inserted in an arm vein and flushed with heparinM 
saline solution. Patients were then allowed to rest supine in 
aquietroomfor3OmiuFivemlofbloodwasplacedintoa 
prechilled tube containin8 txduced glutathione and ethyl- 
enebis(oxyethylene-nitrilo) tetma&c acid (EGTA) for mea- 
surement of plasma norepinephrine. The sample was centri- 
~withinlhat4”Cat2,500rpmf~12min.Plasmawas 
stored at ~-20°C. Five ml each for plasma renin activity, 
arginine vasopressin and atrial natriuretic peptide analysis 
was placed into prechhlcd evacuated tubes containing so- 
dium ethylenediaminetetraacetic acid (EM’A). The three 
tubes were mixed gently and placed on ice and centrit@d 
within I h of coUection at4°C at 2,500 rpm for 12 min. The 
supcrnatant plasma was stored as for plasma wmpinephrine. 
NcllFabormoae assays. Samples from all the centers were 
shipped on dry ice for analysis to the SOLVD nemohormone 
core laboratory at the University of Texas Medical School 
at Houston. Plasma notepinephrine was measured by a 
radioenzymaticmethod(11).plesmareniaactivitywasmea- 
sured using the mod&d radioiiunoassay Whnique of 
Sealey and Laragh (12). Plasma argGne vawpressia and 
atrial natriuretic peptide were meesuced by a simph6ed 
mdioimmunoassay usin9 commer&Uy available antiiies 
(13). AU samples were analyzed in a blinded manner without 
knowledqe of the patients’ charac&stics. 
~and~afmys. Theradioenxy- 
n& assay for plasma rmrepinephrine has a sensilivi~ of 
1 pg/ml with a sample to blank radioactivity count t& of 
>2 and an interassay coe&ient of variation of6.196 (dCu- 
lated fnrm 20 different assays done consecutively on 20 
d&rent days). The radioimmunoassay for plasma R&I 
activity was dependent on the sensitivity of the antibody 
usedintheassaythatw~reliablydetect2pgd~~n- 
sin I (sample to blank ratio 2). This assay could detect VW 
low plasma renin activity (0.1 n&nl per h). The interassaY 
dcient of va&ion for plasma renin activity WBS 12.6%. 
m ~B~~D~RuBDRsR~ for atrial ~~~tbeti~ peptide bus R 

















multiple dhcter method (14). The left veatrhh dimelk 
sionswemmeamredbehvthetipofthemitmlleabtsat 







Statbhl me&b. Between-Lgoup dilhences were 
evaluated by chi-square tests (categoric variables) or 
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diaa 4.3 cm, hterqm& mnge 3.9 to 4.8 cm; group II 





median 1.15, ilmmpmb raugc 0.70 to 2.48; group II 
JACC Vol. 22, No. 4 6uppkmcnt AJ 
October lS3946Ad3A 
FYpre 1. Graphs showing s-t increases in plasma 
wreplnephrlne @NE), plasma renln a&$ 0. plasma 
arginlne vasapressin (AVP) aad atrial natriuretic peptide 
(AIWkveh3inS6cmtmlsu&iec&41patientswithpnl- 
mmlary con&estion on chest x-ray mm end left venuicular 
&ctiou fraction 0 AS% (group ll) and 89 patients with 
pulmonary cimgestion and an ejection fraction ~45% 
@roup9.rbklianvahlesandhterq~~s(z5%to 
75%) are show0 for the four neurohormones. CHF = 
congestive heart failure. 
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(1.4-2.4) (1.7~S.1) (l.D-3.5) 
median 0.82, interquartile range 0.66 to 1.82; p = NS 
between twoups). 
Plasma A When compared with values in 
control subjects, the median values and the interguutile 
ranges for all four q eutuhormones were sign&antly higher 
in patients in group I (plasma norepinephrine: control sub 
jects 316 [range 246 to 4461 vs. 490 [range 350 to 6981 pg/ml, 
p < 0.0991; plasma renin activity 0.6 [rauge 0.3 to O.l?J vs. 2.5 
[range 05 to 8.7) ng/ml per h, p < 0.001; atrial natrhuetic 
peptide 48 [range 31 to 641 vs. 114 [rang 54 to 2251 pgM, 
p < 0.0001 and aginine vasopressin 1.8 [range 1.4 to 2.4) 
vs. 2.4 [taqge 1.9 to 3.51 p&l, p < 0.0001, respectively) 
(Fig. 1). However, when control subjects were wmpwed 
with the patients iu group II, only a&tine vasopressin and 
plasnultwlinactivitywere~tlyhigheriu#roupII 
(at@uine vasopresshu control subjects 1.8 [range 1 A to 2.41 
vs. 2.2 [rJul@ 1.7 to 3.1) p&l& p < 0.02 and PhSBlB I’Ulifl 
B&ity 0.55 [range 0.3 to 0.9) vs. 0.9 [rauge 0.4 to 2.11, p < 
0.02, respectively) (FG. 1). Compared with @ieats in group 
II,thO!#?iIlgOUpIWitllpllhO~COllgeStiOllandh~ 
&ction flaction had signikmt increases in pla!ma norepi- 
nepbrine (p c 0.002), pla!ima r&n activity (p < 0.02) and 
atrial mtriuretic peptide (p e 0.007) levels. Because of 
basehneimb&mxsingeuderbetweengroupsIandII,we 








In a prekls study (17), we dent- that the 
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decrease in lelt ventticular ejection lkion. The&k, we 
examined whether such a cor&tion existed in patients in 
~upI.TaMe2and~2show~correlationbetweeu 
ejection fraction measured in the patients by two- 
dimensional ecw and the various neuiohor- 
monesforthepatieotswith&ctionktions45%and 
puhuonary congestion on chest X-ray 6lm. The increase in 
plasmaueurohomlones,witbtheexcepkmofrqilGleva- 
sopressin,correlatedsiguifktlywithadecreaseinejoction 
fraction in these patients. In contmst, no such con&& 
was present between a change in ejection lkction and 
neurohormones in patients with &ction ktion >4596 aud 
~~tion@ollpII).BeUM!llakltswitba 
Iow&ctionfmctionaremorelikelytobe~laWer 




tmmmbmt dim& or angiotensin-convertin9 enzyme la- 
hiitherapy,orboth.Evenaftera@stiq9forthedilfer- 
ences in drug treatment, plasnz norepinepbrime and atrial 
murhueGcpepti&weresiga&mUyelevatedinp&ntsiu 
lpttPI,~~~~~~btoup~~ . 
llcqm#h p < 0.02, atrisl natmue@ peptide p < 
















PNE PRA AVIJ ANP 
(irmrpI+ mat GmopI Gmllpu Gmprpr GmNp u bPI Group11 
Tw(Jb) 88 39 87 39 73 34 72 34 
r&l -0.27 Iif -6.03 -0.03 a14 -0.45 0.10 
Ph 0.02 0.u NS NS NS O.OW NS 
LvyItdicdimmsim(c4 
Na a9 38 87 39 73 34 72 34 
ho a17 -a15 a36 0.03 0.12 -0.18 a33 a01 
Pd NS NS aam NS NS NS 0.005 NS 
Lvdiantolicdimda(cm3 
No. 86 36 87 39 73 34 72 34 
fha On -a12 a37 0.17 0.16 -0.06 0.20 a10 
,Pzz&m,, 
NS NS aam NS NS NS NS NS 
No. 88 37 87 38 73 33 72 33 
rho air 0.37 -0.M -0.19 a26 -0.13 0.37 0.64 
PVb NS a03 NS NS a03 NS 0.005 0.m1 
crmtio 
No. 72 ,29 72 30 61 26 60 26 
lb OAJE a29 -0.12 -0.69 -0.09 a62 0.37 a26 
PvdIw NS NS NS NS NS NS 0.W NS 
lilm#plaslnaretlitlaetiviiandatrial-peptidewere (rho 0.33, p < O.oas). This is consistent with the obsemtim 
St&iStieaUyrad~y-Witheitberleftahial that of the four neurohormones xamined, atrial natriuretic 
ShUdft-Systolic8llddiastolic~SiOnS peptide Showed the best comlation with cardiothoracic ratio 
(Table 2). However, the best curdah was obserwd on chest X-ray 6lm (rho 0.37, p < 0.004). Although in 
betweenpla8maatridnatri~cpepti&levelaandleftatrial patients with puhmry vascular congestion and ejection 
size (rho 0.37, p c am) aad left venm systolic volume fktion >45% (gmup II), atrial natriuretic peptide levels 
,poo PLASMA NOREPINEPHRINE 
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PLASMA RENIN ACTIVITY 
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were not signikntly elevated above those in the control 
group, a signihcant datiOn was found between left atrial 
sixe and atrial natriuretic peptide levels (rho 0.64. p e 
0.001). This iinding strongly su99ests that an increase in 
atrial natriuretic peptide levels can develop without the 
presence of systoiic dysfunction and correlates with the 
increase in left atrial dimension. 
Con9estive heart failure is a clinical syndrome associated 
with a broad spectrum ofaIteration in myocardial function 
with varyiqg wmponents of systolic and diastolic impair- 
ment. Neurohumoral ctivation is an important manifesta- 
tion in patients with colyestive heart failure. Previous tud- 
ies exam&g the q eutuhonnonal alterations have focused 
mainly on patients with severe impairment in systolic con- 
tractility. It is not clear whether patients with symptoms of 
congestive heart failure and preserved systolic function have 
similar alterations in neurohumoral mechanisms. In our 
study, we examined patients from the SOLVD Registry, 
where patients were not recruited on the basis of eligibility 
~atrialofI#ltients~~congestiveheart~andare 
thus more representative of the general pop&ion of pa- 
tients with left ventrictdar dysfunction. These results show 
that compared with age-matched control subjects, patients 
with puhuonsry vascuk congestion and preserved systolic 
function (&ction fraction >45%) have no increase in neu- 
rohormones except for arginine vasopressin and plasma 
nnin activity. In contrast, patients with puhuonary vascuhlr 
congestion and impaired systolic function (ejection fraction 
s45%) have a sign&ant increase in all four neurohormones 
studied. 
The increase in three neurohormones (plasma norepi- 
nephrine, plasmarenin activity aud atrial natriuretic peptide) 
wasstatisticalIyandsi9ni6cantIy~withIeRventri~ 
ular ejection fmction in patients with systolic dysfunction, 
with atriaI natriuretic peptide showiu9 the best correbttion. 
This reMion was demonstrable even akr a@st@ for the 
et&t of dtug therapy on various q emohormuues. The 
absohtte plasma norepiuephrine l vei in patients with con- 
gestive heart faihue is influeuced by alterations in nem7maI 
uptake, cIearauce and metabolism of norepiuephrine re- 
leased from the sympathetic nerve endiugs. However, the 
measurement of e&rent sympathetic nerve tra& by intra- 
nemonaltecordiagintheperonealnerveinpatientswith 
congesGve heart faihue demonstrates vidence of increased 
centraI sympathetic outRow and elevated plasma norepi- 
nephrine levels in these patients (18). If the stimuhts for 
activationdthesympak?Gcnervous system is poor pump 
function, then it is uot unreasonable to expect a correlation 
between left ventricuhu &ction fraction and plasma norepi- 
nephk levels. We found a reIativeIy weak correlation 
betweenpIasmanorepiuephriue,whichhasaRobeenob 
served in other cIinicaI studies (1930 iu patients with 
moderatetoseveresymI&uusofheartfaihue.lkewaS 
also a weak correlation between ejection fraction and pb 
renin activity. This relation with ejection frac& persisted 
despite adjusting for the effect of concomitant thw tifi 
diuretic agents and an&ensin-converting enzyme inhibi- 
tars. Ahhough several studies have reported the stimulation 
of the renin-atgiotensin system in congestive heart failure, 
there is uo agreement on the frequency or amplitude of this 
stimukion in patients with varying degrees of congestive 
heart failure. Dza~ et al. (21) repotted that the system is 
marlrcdly activated during acute decompensation but near 
normal when patients have recovered from the acute epi- 
sode. Therefore, the clinical status of the patient with 
amgestive heart faihue (compensated or decompensated) 
wiil aIkt the measured plasma renin activity levels. Fur- 
ther, diuretic use and sodium restriction a&ct the renin- 
angiotensin system and increase plasma reniu activity levels 
(2223). However, Anand et al. (24) showed that five of eight 
patients with advanced untreated chronic congestive heart 
failure with salt and water retention had elevated plasma 
renin activity levels. Similar findings have been reported by 
Brown et al. @!I) in untreated patients with congestive heart 
tkihue. These data suggest hat depending on the cohort of 
patients investigated, the clinical severity of congestive 
heart failure involved and the medications used, plasma 
renin activity levels can vary sign&u&y. 
Of all the neurohormones, atrial nahiuretic peptide 
showed the strongest wrielation with &ction fraction. 
Atrial natriuretic peptide is synthesked in the myocardium 
and released mainly in response to increased atrial s&etch@ 
(26). Plasma atrial q atriuretic peptide levels iuuease with 
increased atrial pressures and atrial stretch in patieuts with 
worsening failure (27,28). IIara et al. (29) found atrial natri- 
uretic peptide levels in plasma to correlate inversely with the 
level of ejection fractiofl aud directly with the severity of 
congestive heart faihue. SimiIarIy, Rouleau et al. (30) found 
aninversecor&tionbetweenatriaInatriureticpeptideand 
cardiac index. In this study, atrial natrhuetic peptide c0zre 
iatedwitIlleftatrialsixeandthestron9estwrmbuumwas 
found in patients with preserved systolic Gmction. This 
hdiBgiSiBkeepingWithtlleS~tiolltilBtttle~iO 
ahiatmtriweticpeptideledsdeVelopseRrly~aaresultof 
distension of the left atrium and tends to correlate with left 
atrial &~&MI. Ihwver, in wntrast to patients with 
pmdon+mtIy diastolic dystktion who experience dv 
tit epi~des d 811 iacrea~e in left ventticular end- 
diastOlic pressure, patient!i with impaid SYStoliC Contra&- 
ity tend to have a sustained kreaseinkftventrkuIar 
end-diastolic pressure. This sustained increase may reStdt in 
chronic stretching and alteration in left atrial Wmplisllce. 
which may be one of the expkations kr the kss striking 
~ti0n ktweeu atrial ~triuretic peptide IeveIs and left 
atrial dimension in patients with impaired Sy!3tOliC let? Wlk 
tricular funCtiOn (31). 






























- Plasma neurohWmonal levels in patients 
withcongestiveheartMurearedependentonacomplex 
interplay~sym@nlM,medication!5usedaadthedegree 
of left ventricuk dysbction. In the absence of left vent+ 
b d-9 -mechanismsareaotacti- 
vatedexceptRbraminimalincrease in the level of aqinine 
vaaopressin aad plasma renin activity. with the onset of 
systolic left ventricular dysfuacb, activation of plasma 
. 
ncmpqhb and atrid natriuetic peptide develops in 
these patient8. This study h the SOLvD xkgi8t1~1 broad- 
~s~~taOdin#ofneurohumoAactivationthatwas 
P=vioulVbtaiWdfIDmtheorigiMlsoLvDneurohor- 
monaI study (17) aad its applicability to patients with plll- 
moaSry cOn@stion and with or without systolic dysfbction 
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